Key terms
About XOMA
XOMA Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest XOMA news
Yesterday
6:17am ET
Analysts Are Bullish on These Healthcare Stocks: Exelixis (EXEL), Cyclo Therapeutics (CYTH)
Apr 30
7:45am ET
Xoma acquires economic interest in three assets from Dare Bioscience
Apr 30
7:42am ET
Dare Bioscience secures $22M in non-dilutive strategic royalty financing
Apr 29
6:26am ET
Xoma initiated with an Outperform at Leerink
Apr 25
7:34am ET
Xoma earns $9M milestone as FDA grants approval of Day One’s NDA for OJEMDA
Apr 25
6:20am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Apr 03
9:14am ET
Xoma announces closing of tender offer
Mar 11
12:01pm ET
Analysts Conflicted on These Healthcare Names: Xoma (XOMA) and Lexicon Pharmaceuticals (LXRX)
Mar 09
1:01am ET
Xoma Corp. Is Worried About This – Should You Be Worried Too?
Mar 08
4:38pm ET
Xoma files $200M mixed securities shelf
Mar 08
7:35am ET
Xoma reports 2023 EPS ($4.04) vs. ($1.98) last year
Feb 16
11:25am ET
Strategic Acquisitions and Royalty Income Streams Justify Buy Rating for Xoma
Feb 16
11:25am ET
Xoma acquisition boosts royalty growth potential, says H.C. Wainwright
Feb 16
9:22am ET
Xoma Corp Secures Merger with Kinnate Biopharma Inc.
Feb 16
8:05am ET
Xoma to acquire Kinnate for between $2.3352-$2.5879 per share plus CVR
Feb 16
8:03am ET
Xoma to acquire Kinnate Biopharma for between $2.3352-$2.5879 per share plus CVR
No recent press releases are available for XOMA
XOMA Financials
Key terms
Ad Feedback
XOMA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
XOMA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
